Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 970Neoplasms 767Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 577Colorectal Neoplasms 503Lung Neoplasms 447Neoplasm Metastasis 408Multiple Myeloma 376Leukemia, Myeloid, Acute 358Ovarian Neoplasms 311Pancreatic Neoplasms 306Melanoma 275Squamous Cell Carcinoma of Head and Neck 259Recurrence 248Carcinoma, Hepatocellular 233Glioblastoma 225Brain Neoplasms 221Head and Neck Neoplasms 202Triple Negative Breast Neoplasms 200Carcinoma, Renal Cell 200Lymphoma 192Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Stomach Neoplasms 189Endometrial Neoplasms 179Lymphoma, Non-Hodgkin 175Sarcoma 169Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 159

Interventions

Midazolam 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pamiparib 1lenvatinib 1drospirenone 1Temozolomide 1HMPL-013 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancies × 90 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

NCT07426757 2026-06-01

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Pfizer

Phase 1 Recruiting
120 enrolled

Advanced Malignancies

NCT07340190 2026-04-02

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Novartis

Phase 1 Not yet recruiting
24 enrolled

Advanced Malignancies

NCT05351697 2026-03-17

BR105-I

BioRay Pharmaceutical Co., Ltd.

Phase 1 Terminated
31 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡